CompletedInterventionalPhase 1Last updated Oct 14, 2016

Study of Multiple Oral Dosing to Evaluate the Safety and the Pharmacokinetic Drug-drug Interaction of Telmisartan/Amlodipine and Rosuvastatin in Healthy Male Volunteers

NCT02933658

Overview

ClinicalTrials.gov ID: NCT02933658
Lead Sponsor: Daewon Pharmaceutical Co., Ltd.INDUSTRY
Brief Summary: A non-randomized, two-arm, single-sequence, crossover, open label, multiple oral dosing clinical trial to evaluate the safety and the pharmacokinetic drug-drug interaction of Telmisartan/Amlodipine and Rosuvastatin in healthy male volunteers
Study Type: Interventional

Status

Study Record Dates

NCT02233218Completed

The Pharmacokinetic Drug-drug Interaction and Safety of Telmisartan/Amlodipine and Rosuvastatin in Healthy Male Volunteers

NCT02387619Completed

The Pharmacokinetic Drug Interaction Between Rosuvastatin and Telmisartan/Amlodipine

NCT02951962Completed

A Study to Investigate Pharmacokinetic Drug Interaction and Safety of Telmisartan/Amlodipine and Rosuvastatin

NCT02047175Completed

CKD-346 DDI Study(Telmisartan/S-Amlodipine, Rosuvastatin)

NCT03461081Completed

Drug-drug Interaction Following Oral Administration of Telmisartan/Amlodipine and Atorvastatin in Healthy Adult Volunteers

NCT03889145Completed

A Study to Evaluate the Drug-drug Interaction Between Telmisartan, Amlodipine and Hydrochlorothiazide